keyword
MENU ▼
Read by QxMD icon Read
search

NCCN

keyword
https://www.readbyqxmd.com/read/29030906/effects-of-interruptions-of-external-beam-radiation-therapy-on-outcomes-in-patients-with-prostate-cancer
#1
Yanqun Dong, Nicholas G Zaorsky, Tianyu Li, Thomas M Churilla, Rosalia Viterbo, Mark L Sobczak, Marc C Smaldone, David Yt Chen, Robert G Uzzo, Mark A Hallman, Eric M Horwitz
INTRODUCTION: To evaluate if interruptions of external beam radiation therapy impact outcomes in men with localized prostate cancer (PCa). METHODS: We included men with localized PCa treated with three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) of escalated dose (≥74 Gy in 1.8 or 2 Gy fractions) between 1992 and 2013 at an NCI-designated cancer centre. Men receiving androgen deprivation therapy were excluded. The non-treatment day ratio (NTDR) was defined as the number of non-treatment days divided by the total elapsed days of therapy...
October 13, 2017: Journal of Medical Imaging and Radiation Oncology
https://www.readbyqxmd.com/read/29028665/gynecologic-cancer-in-hiv-infected-women-treatment-and-outcomes-in-a-multi-institutional-cohort
#2
Kimberly L Levinson, David J Riedel, Laureen S Ojalvo, Wesley Chan, Ana M Azngarita, Amanda N Fader, Anne F Rositch
OBJECTIVE: To evaluate gynecologic cancer treatments in Human Immunodeficiency Virus (HIV) infected women for adherence to National Comprehensive Cancer Network (NCCN) guidelines and to describe survival by adherence to guidelines. DESIGN: Beyond cervical cancer, there is little data on treatment and outcomes for these women. This is a retrospective cohort study of HIV infected women with gynecologic cancers. METHODS: HIV infected women with gynecologic cancers from 2000-2015 were identified at two urban, comprehensive cancer centers...
October 12, 2017: AIDS
https://www.readbyqxmd.com/read/29025982/appropriate-use-criteria-for-somatostatin-receptor-pet-imaging-in-neuroendocrine-tumors
#3
Thomas A Hope, Emily Bergsland, Murat Fani Bozkurt, Michael M Graham, Anthony P Heaney, Ken Herrmann, James R Howe, Matthew H Kulke, Pamela L Kunz, Josh Mailman, Lawrence May, David C Metz, Corina Millo, Sue O'Dorisio, Diane L Reidy-Lagunes, Michael C Soulen, Jonathan R Strosberg
Somatostatin receptor positron emission tomography (SSTR-PET) is an imaging modality for patients with neuroendocrine tumors (NETs) that has demonstrated a significant improvement over conventional imaging (CI). SSTR-PET should replace In-111 pentetreotide scintigraphy (OctreoScan) in all indications in which SSTR scintigraphy is currently being used. These appropriate use criteria (AUC) are intended to aid referring medical practitioners in the appropriate use of SSTR-PET for imaging of patients with NETs, and the indications were evaluated in well-differentiated NETs...
October 12, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29024628/biologico-clinical-significance-of-dnmt3a-variants-expression-in-acute-myeloid-leukemia
#4
Na Lin, Wei Fu, Chen Zhao, Bixin Li, Xiaojing Yan, Yan Li
DNA methyltransferase 3A (DNMT3A) catalyzes de novo DNA methylation and plays important roles in the pathogenesis of acute myeloid leukemia. However, the expression status of DNMT3A variants in acute myeloid leukemia remains obscure. This study aimed to assess the expression levels of alternative splicing of DNMT3A variants and explore their roles in acute myeloid leukemia (AML). DNMT3A variants gene expression were assessed, measuring their effects on cell proliferation. In addition, the expression of DNMT3A variants were evaluated in acute myeloid leukemia patients...
October 9, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28994485/modified-risk-stratification-grouping-using-standard-clinical-and-biopsy-information-for-patients-undergoing-radical-prostatectomy-results-from-search
#5
Zachary S Zumsteg, Zinan Chen, Lauren E Howard, Christopher L Amling, William J Aronson, Matthew R Cooperberg, Christopher J Kane, Martha K Terris, Daniel E Spratt, Howard M Sandler, Stephen J Freedland
INTRODUCTION: Prostate cancer is a heterogeneous disease, and risk stratification systems have been proposed to guide treatment decisions. However, significant heterogeneity remains for those with unfavorable-risk disease. METHODS: This study included 3335 patients undergoing radical prostatectomy without adjuvant radiotherapy in the SEARCH database. High-risk patients were dichotomized into standard and very high-risk (VHR) groups based on primary Gleason pattern, percentage of positive biopsy cores (PPBC), number of NCCN high-risk factors, and stage T3b-T4 disease...
October 10, 2017: Prostate
https://www.readbyqxmd.com/read/28990128/a-single-center-retrospective-analysis-to-compare-the-efficacy-and-safety-of-filgrastim-sndz-to-filgrastim-for-prophylaxis-of-chemotherapy-induced-neutropenia-and-for-neutrophil-recovery-following-autologous-stem-cell-transplantation
#6
Julia Zecchini, Kendra Yum, Amir Steinberg, Cardinale Smith, Sara Kim
Filgrastim-sndz (Zarxio®) was approved by the FDA in March 2015 as a biosimilar product of its reference product, filgrastim (Neupogen®) for all five indications. The NCCN Clinical Practice Guidelines has incorporated filgrastim-sndz into its recommendations as a category 1 recommendation for use in settings of febrile neutropenia, myelosuppressive chemotherapy administration, and post-hematopoietic stem cell transplant (HSCT). As a cost-saving initiative, our institution switched from filgrastim to filgrastim-sndz for all indications starting in March 2016...
October 8, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28982750/bladder-cancer-version-5-2017-nccn-clinical-practice-guidelines-in-oncology
#7
Philippe E Spiess, Neeraj Agarwal, Rick Bangs, Stephen A Boorjian, Mark K Buyyounouski, Peter E Clark, Tracy M Downs, Jason A Efstathiou, Thomas W Flaig, Terence Friedlander, Richard E Greenberg, Khurshid A Guru, Noah Hahn, Harry W Herr, Christopher Hoimes, Brant A Inman, Masahito Jimbo, A Karim Kader, Subodh M Lele, Joshua J Meeks, Jeff Michalski, Jeffrey S Montgomery, Lance C Pagliaro, Sumanta K Pal, Anthony Patterson, Elizabeth R Plimack, Kamal S Pohar, Michael P Porter, Mark A Preston, Wade J Sexton, Arlene O Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A Dwyer, Lisa A Gurski
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up...
October 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28982745/nccn-guidelines-insights-myeloproliferative-neoplasms-version-2-2018
#8
Ruben A Mesa, Catriona Jamieson, Ravi Bhatia, Michael W Deininger, Christopher D Fletcher, Aaron T Gerds, Ivana Gojo, Jason Gotlib, Krishna Gundabolu, Gabriela Hobbs, Brandon McMahon, Sanjay R Mohan, Stephen Oh, Eric Padron, Nikolaos Papadantonakis, Philip Pancari, Nikolai Podoltsev, Raajit Rampal, Erik Ranheim, Vishnu Reddy, Lindsay A M Rein, Bart Scott, David S Snyder, Brady L Stein, Moshe Talpaz, Srdan Verstovsek, Martha Wadleigh, Eunice S Wang, Mary Anne Bergman, Kristina M Gregory, Hema Sundar
Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET...
October 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28982742/implementation-framework-for-nccn-guidelines
#9
Abdul Rahman Jazieh, Joan S McClure, Robert W Carlson
No abstract text is available yet for this article.
October 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28977975/prognostic-clinicopathologic-factors-in-carcinoma-of-unknown-primary-origin-a-study-of-106-consecutive-cases
#10
Junjeong Choi, Ji Hae Nahm, Sang Kyum Kim
A heterogeneous group of cancers for which the site of origin remains occult after detailed investigations is defined as carcinomas of unknown primary origin (CUPs). Because patients with CUP have a dismal prognosis, we have analyzed CUPs to highlight the implication of clinicopathologic factors related with patient survival. A total of 106 consecutive cases of CUP were collected. A two-step strategy of immunohistochemistry to assess CUPs according NCCN Guidelines is used to separate carcinomatous tumors and subtype carcinomas...
September 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28975822/multimodality-management-of-borderline-resectable-pancreatic-neuroendocrine-tumors-report-of-a-single-institution-experience
#11
Chenwi M Ambe, Phuong Nguyen, Barbara A Centeno, Junsung Choi, Jonathan Strosberg, Larry Kvols, Pamela Hodul, Sarah Hoffe, Mokenge P Malafa
BACKGROUND: Pancreatic neuroendocrine tumors (PanNETs) constitute approximately 3% of pancreatic neoplasms. Like patients with pancreatic ductal adenocarcinoma (PDAC), some of these patients present with "borderline resectable disease." For these patients, an optimal treatment approach is lacking. We report our institution's experience with borderline resectable PanNETs using multimodality treatment. METHODS: We identified patients with borderline resectable PanNETs who had received neoadjuvant therapy at our institution between 2000 and 2013...
October 2017: Cancer Control: Journal of the Moffitt Cancer Center
https://www.readbyqxmd.com/read/28954449/-clinical-analysis-of-76-cases-of-sentinel-lymph-node-detection-in-cervical-cancer-and-endometrial-cancer
#12
S C Liang, Z Q Wang, J L Wang
Objective: To evaluate the feasibility and clinical value of identifying sentinel lymph node (SLN) and to assess possible factors associated with detection rate in both cervical cancer and endometrial cancer. Methods: Retrospective study of 76 cases (39 with cervical cancer and 37 with endometrial cancer) were conducted in Peking University People's Hospital. All patients underwent SLN biopsy with tracers of indocyanine green (ICG) and (or) carbon nanoparticles. All mapped SLN was resected and followed by procedures that systematic pelvic lymphadenectomy and hysterectomy according to National Comprehensive Cancer Network (NCCN) guidelines...
September 25, 2017: Zhonghua Fu Chan Ke za Zhi
https://www.readbyqxmd.com/read/28952411/clinical-development-of-mtor-inhibitors-for-renal-cancer
#13
Michele Ghidini, Fausto Petrelli, Antonio Ghidini, Gianluca Tomasello, Jens Claus Hahne, Rodolfo Passalacqua, Sandro Barni
Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. In the last 10 years, clinical trials have established multitargeted tyrosine kinase inhibitors (TKIs) as the standard first-line treatment in patients with metastatic disease. Multiple agents are now available for treatment in subsequent lines.The mammalian target of rapamycin (mTOR) inhibitors (e.g., everolimus alone or with lenvatinib) are among the most effective options. Areas covered: This paper provides a complete and updated overview on mTOR inhibitors for the treatment of advanced RCC...
November 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28951747/prostate-cancer-specific-death-in-brachytherapy-treated-high-risk-patients-stratified-by-pre-treatment-psa
#14
Gregory S Merrick, Robert W Galbreath, Wayne M Butler, Ryan Fiano, Edward Adamovich
PURPOSE: To evaluate prostate-cancer specific mortality (PCSM) in a cohort of high-risk patients treated with a permanent prostate brachytherapy approach, stratified by pre-treatment PSA. MATERIAL AND METHODS: 448 high-risk patients (NCCN criteria) underwent permanent prostate brachytherapy. High risk patients were stratified by pre-treatment PSA (≤ 10.0, 10.1-20, and > 20 ng/ml). Biochemical failure (BF), prostate cancer-specific mortality (PCSM), distant failure (DM), and overall mortality (OM) were assessed as a function of prognostic group...
August 2017: Journal of Contemporary Brachytherapy
https://www.readbyqxmd.com/read/28948329/surgery-for-pancreatic-cancer-critical-radiologic-findings-for-clinical-decision-making
#15
Annabelle L Fonseca, Jason B Fleming
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States, with an estimated 53,670 new cases diagnosed and an estimated 43,090 deaths in 2017. This high mortality rate is in part due to the small percentage of patients diagnosed with local disease, as well as the biologically aggressive nature of the disease. While only 10-20% of patients will present with surgically resectable disease, this is the only possible curative therapy. Five-year survival of resected pancreatic cancer ranges from 12 to 27%...
September 25, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28942516/approach-to-mpn-symptom-assessment
#16
REVIEW
Holly Geyer, Ruben A Mesa
PURPOSE OF REVIEW: Myeloproliferative neoplasms (MPNs) are recognized for their debilitating symptom burdens. The purpose of this review is to understand the complexity of the MPN symptom burden and identify how validated MPN Patient Reported Outcome (PRO) tools may be integrated into clinical practice to assess the MPN symptom burden. RECENT FINDINGS: Significant heterogeneity exists both within and between MPN subtypes. Surrogates of disease burden such as risk scores and MPN chronicity often fail to correlate with symptomatic burden...
September 23, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28941920/genomic-scores-are-independent-of-disease-volume-in-men-with-favorable-risk-prostate-cancer-implications-for-choosing-men-for-active-surveillance
#17
Yaw A Nyame, Dominic C Grimberg, Daniel J Greene, Karishma Gupta, Ganesh K Kartha, Ryan Berglund, Michael Gong, Andrew J Stephenson, Cristina Magi-Galluzzi, Eric A Klein
OBJECTIVE: To determine if disease volume at prostate biopsy correlates with genomic scores among men with favorable risk prostate cancer. METHODS: All men with NCCN very low (VLR) and low risk (LR) disease and OncotypeDx Prostate testing at our institution from 2013 to 2016 were identified. Volume of disease was characterized as percent of positive cores, number of cores with >50% involvement, largest involvement of any single core, and PSA density. Nonparametric testing was performed to compare the median genomic prostate score (GPS) and likelihood of favorable pathology (LFP) between quartiles of disease volume...
September 20, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28925011/trends-in-active-surveillance-for-very-low-risk-prostate-cancer-do-guidelines-influence-modern-practice
#18
Rahul R Parikh, Sinae Kim, Mark N Stein, Bruce G Haffty, Isaac Y Kim, Sharad Goyal
As recommended by current NCCN guidelines, patients with very low-risk prostate cancer may be treated with active surveillance (AS), but this may be underutilized. Using the National Cancer Database (NCDB), we identified men (2010-2013) with biopsy-proven, very low-risk prostate cancer that met AS criteria as suggested by Epstein (stage ≤ T1c; Gleason score (GS) ≤ 6; PSA < 10; and ≤2 [or <33%] positive biopsy cores) and aged ≤76, and low comorbidity index (Charlson-Deyo score = 0). For those patients meeting this criteria, we performed generalized estimation equation (GEE) method with incorporation of correlation in patients clustered within facility to determine the likelihood of undergoing AS...
September 18, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28900987/-consensus-and-controversy-of-endoscopic-diagnosis-and-treatment-of-gastroenteropancreatic-neuroendocrine-tumors
#19
Huishan Chen, Ye Chen
Neuroendocrine neoplasms(NENs) are relatively rare tumors originating from the diffuse neuroendocrine system, and gastrointestinal tract is one of the most common location of the tumors. Currently, the European Neuroendocrine Neoplasm Society (ENETS) and the National Comprehensive Cancer Network (NCCN) have released the international guidelines for NENs management. And also, experts from Chinese Society of Clinical Oncology (CSCO) have proposed "The Consensus on Gastroenteropancreatic Neuroendocrine Neoplasm in China" in 2016, which is also one of the most important reference standard for the diagnosis and treatment of gastroenteropancreatic(GEP) NENs in China...
September 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28900986/-consensus-and-controversy-on-subtype-classification-of-gastric-neuroendocrine-neoplasms
#20
Huangying Tan
Gastric neuroendocrine neoplasms (g-NENs) are a heterogeneous group of tumors. Often silent, g-NENs may however be aggressive and sometimes mimic the course of gastric adenocarcinoma. Well-differentiated gastric neuroendocrine tumors (NET) can be subclassified into 3 distinct groups (type1, type 2 and type 3) according to Neuroendocrine Neoplasm Society (ENETS) guideline version 2006 as well as North America Neuroendocrine Tumor Society (NANETS) and National Comprehensive Cancer Network (NCCN) guidelines. However, since the publication of ENETS guideline version 2012, the subtype classification of g-NENs has been confusing due to the revised definition of type 3 g-NEN in versions 2012 and 2016...
September 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
keyword
keyword
30821
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"